deferiprone has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boyle, JP; Duce, JA; Hettiarachchi, NT; Hunter, M; Lewis, FW; Mousadoust, M; Peers, CS; Tétard, D; Tsatsanis, A; Workman, DG | 1 |
| Applová, L; Franz, KJ; Hašková, P; Homola, P; Jansová, H; Roh, J; Šimůnek, T; Vávrová, K | 1 |
2 other study(ies) available for deferiprone and oxidopamine
| Article | Year |
|---|---|
Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators.
Topics: Cell Line; Crystallography, X-Ray; Deferiprone; Humans; Iron Chelating Agents; Models, Molecular; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease, Secondary; Pyridones | 2015 |
Examination of diverse iron-chelating agents for the protection of differentiated PC12 cells against oxidative injury induced by 6-hydroxydopamine and dopamine.
Topics: Animals; Catecholamines; Deferasirox; Deferiprone; Deferoxamine; Dopamine; Iron; Iron Chelating Agents; Iron Overload; Oxidative Stress; Oxidopamine; PC12 Cells; Rats | 2022 |